Seminars in Hematology
Volume 44, Issue 2 , Pages 77-84 , April 2007

Plasma Coagulation Factor Levels in Venous Thrombosis

References 

  1. Anderson FA, Wheeler HB, Goldberg RJ, Hosmer DW, Patwardhan NA, Jovanovic B, et al. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism (The Worcester DVT Study). Arch Intern Med. 1991;151:933–938
  2. Carter CJ. The natural history and epidemiology of venous thrombosis. Prog Cardiovasc Dis. 1994;36:423–438
  3. Brandjes DP, Büller HR, Heijboer H, Huisman MV, de Rijk M, Jagt H, et al. Randomised trial of effect of compression stockings in patients with symptomatic proximal-vein thrombosis. Lancet. 1997;349:759–762
  4. Rosendaal FR. Venous thrombosis: A multicausal disease. Lancet. 1999;353:1167–1173
  5. Koster T, Rosendaal FR, Reitsma PH, van der Velden PA, Briët E, Vandenbroucke JP. Factor VII and fibrinogen levels as risk factors for venous thrombosis (A case-control study of plasma levels and DNA polymorphisms—The Leiden Thrombophilia Study (LETS)). Thromb Haemost. 1994;71:719–722
  6. van Hylckama Vlieg A, Rosendaal FR. High levels of fibrinogen are associated with the risk of deep venous thrombosis mainly in the elderly. J Thromb Haemost. 2003;1:2677–2678
  7. Austin H, Hooper WC, Lally C, Dilley A, Ellingsen D, Wideman C, et al. Venous thrombosis in relation to fibrinogen and factor VII genes among African-Americans. J Clin Epidemiol. 2000;53:997–1001
  8. Tsai AW, Cushman M, Rosamond WD, Heckbert SR, Tracy RP, Aleksic N, et al. Coagulation factors, inflammation markers, and venous thromboembolism: The Longitudinal Investigation of Thromboembolism Etiology (LITE). Am J Med. 2002;113:636–642
  9. de Maat MP, Verschuur M. Fibrinogen heterogeneity: Inherited and noninherited. Curr Opin Hematol. 2005;12:377–383
  10. Kamphuisen PW, Eikenboom HCJ, Vos HL, Pablo R, Sturk A, Bertina RM, et al. Increased levels of factor VIII and fibrinogen in patients with venous thrombosis are not caused by acute phase reactions. Thromb Haemost. 1999;81:680–683
  11. Renner W, Cichocki L, Forjanics A, Koppel H, Gasser R, Pilger E. G-455A polymorphism of the fibrinogen beta gene and deep vein thrombosis. Eur J Clin Invest. 2002;32:755–758
  12. Uitte de Willige S, De Visser MCH, Houwing-Duistermaat JJ, Rosendaal FR, Vos HL, Bertina RM. Genetic variation in the fibrinogen gamma gene increases the risk for deep venous thrombosis by reducing plasma fibrinogen gamma’ levels. Blood. 2005;106:4176–4183
  13. Bertina RM, van Tilburg NH, de Fouw NJ, Haverkate F. Thrombin, a link between coagulation activation and fibrinolysis. Ann N Y Acad Sci. 1992;667:239–248
  14. Lane DA, Philippou H, Huntington JA. Directing thrombin. Blood. 2005;106:2605–2612
  15. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood. 1996;88:3698–3703
  16. Legnani C, Cosmi B, Valdre L, Boggian O, Bernardi F, Coccheri S, et al. Venous thromboembolism, oral contraceptives and high prothrombin levels. J Thromb Haemost. 2003;1:112–117
  17. Folsom AR, Cushman M, Tsai MY, Heckbert SR, Aleksic N. Prospective study of the G20210A polymorphism in the prothrombin gene, plasma prothrombin concentration, and incidence of venous thromboembolism. Am J Hematol. 2002;71:285–290
  18. Hillarp A, Zoller B, Svensson PJ, Dahlback B. The 20210 A allele of the prothrombin gene is a common risk factor among Swedish outpatients with verified deep venous thrombosis. Thromb Haemost. 1997;78:990–992
  19. Margaglione M, Brancaccio V, Giuliani N, D’Andrea G, Cappucci G, Iannaccone L, et al. Increased risk for venous thrombosis in carriers of the prothrombin G→A20210 gene variant. Ann Intern Med. 1998;129:89–93
  20. Vicente V, Gonzalez-Conejero R, Rivera J, Corral J. The prothrombin gene variant 20210A in venous and arterial thromboembolism. Haematologica. 1999;84:356–362
  21. Soria JM, Almasy L, Souto JC, Tirado I, Borell M, Mateo J, et al. Linkage analysis demonstrates that the prothrombin G20210A mutation jointly influences plasma prothrombin levels and risk of thrombosis. Blood. 2000;95:2780–2785
  22. Ho WK, Hankey GJ, Quinlan DJ, Eikelboom JW. Risk of recurrent venous thromboembolism in patients with common thrombophilia: A systematic review. Arch Intern Med. 2006;166:729–736
  23. Eichinger S, Minar E, Hirschl M, Bialonczyk C, Stain M, Mannhalter C, et al. The risk of early recurrent venous thromboembolism after oral anticoagulant therapy in patients with the G20210A transition in the prothrombin gene. Thromb Haemost. 1999;81:14–17
  24. Christiansen SC, Cannegieter SC, Koster T, Vandenbroucke JP, Rosendaal FR. Thrombophilia, clinical factors, and recurrent venous thrombotic events. JAMA. 2005;293:2352–2361
  25. Ceelie H, Bertina RM, van Hylckama Vlieg A, Rosendaal FR, Vos HL. Polymorphisms in the prothrombin gene and their association with plasma prothrombin levels. Thromb Haemost. 2001;85:1066–1070
  26. Gehring NH, Frede U, Neu-Yilik G, Hundsdoerfer P, Vetter B, Hentze MW, et al. Increased efficiency of mRNA 3′ end formation: A new genetic mechanism contributing to hereditary thrombophilia. Nat Genet. 2001;28:389–392
  27. Carter AM, Sachchithananthan M, Stasinopoulos S, Maurer F, Medcalf RL. Prothrombin G20210A is a bifunctional gene polymorphism. Thromb Haemost. 2002;87:846–853
  28. Ceelie H, Spaargaren-Van Riel CC, Bertina RM, Vos HL. G20210A is a functional mutation in the prothrombin gene; effect on protein levels and 3′-end formation. J Thromb Haemost. 2004;2:119–127
  29. Danckwardt S, Gehring NH, Neu-Yilik G, Hundsdoerfer P, Pforsich M, Frede U, et al. The prothrombin 3′ end formation signal reveals a unique architecture that is sensitive to thrombophilic gain-of-function mutations. Blood. 2004;104:428–435
  30. von Ahsen N, Oellerich M. The intronic prothrombin 19911A>G polymorphism influences splicing efficiency and modulates effects of the 20210G>A polymorphism on mRNA amount and expression in a stable reporter gene assay system. Blood. 2004;103:586–593
  31. Castaman G, Tosetto A, Simioni M, Ruggeri M, Madeo D, Rodeghiero F. Phenotypic APC resistance in carriers of the A20210 prothrombin mutation is associated with an increased risk of venous thrombosis. Thromb Haemost. 2001;86:804–808
  32. Kyrle PA, Mannhalter C, Beguin S, Stumpflen A, Hirschl M, Weltermann A, et al. Clinical studies and thrombin generation in patients homozygous or heterozygous for the G20210A mutation in the prothrombin gene. Arterioscler Thromb Vasc Biol. 1998;18:1287–1291
  33. Curvers J, Thomassen MC, Rimmer J, Hamulyak K, van der Meer J, Tans G, et al. Effects of hereditary and acquired risk factors of venous thrombosis on a thrombin generation-based APC resistance test. Thromb Haemost. 2002;88:5–11
  34. Koenen RR, Tans G, van Oerle R, Hamulyak K, Rosing J, Hackeng TM. The APC-independent anticoagulant activity of protein S in plasma is decreased by elevated prothrombin levels due to the prothrombin G20210A mutation. Blood. 2003;102:1686–1692
  35. Wolberg AS, Monroe DM, Roberts HR, Hoffman M. Elevated prothrombin results in clots with an altered fiber structure: A possible mechanism of the increased thrombotic risk. Blood. 2003;101:3008–3013
  36. Orstavik KH, Magnus P, Reisner H, Berg K, Graham JB, Nance W. Factor VIII and factor IX in a twin population (Evidence for a major effect of ABO locus on factor VIII level). Am J Hum Genet. 1985;37:89–101
  37. Koster T, Blann AD, Briët E, Vandenbroucke JP, Rosendaal FR. Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. Lancet. 1995;345:152–155
  38. Morelli VM, De Visser MCH, Vos HL, Bertina RM, Rosendaal FR. ABO blood group genotypes and the risk of venous thrombosis: Effect of factor V Leiden. J Thromb Haemost. 2005;3:183–185
  39. Souto JC, Almasy L, Borrell M, Blanco-Vaca F, Mateo J, Soria JM, et al. Genetic susceptibility to thrombosis and its relationship to physiological risk factors: The GAIT study (Genetic Analysis of Idiopathic Thrombophilia). Am J Hum Genet. 2000;67:1452–1459
  40. Kraaijenhagen RA, in’t Anker PS, Koopman MM, Reitsma PH, Prins MH, van den Ende A, et al. High plasma concentration of factor VIIIc is a major risk factor for venous thromboembolism. Thromb Haemost. 2000;83:5–9
  41. Lensen R, Bertina RM, Vandenbroucke JP, Rosendaal FR. High factor VIII levels contribute to the thrombotic risk in families with factor V Leiden. Br J Haematol. 2001;114:380–386
  42. Patel RK, Ford E, Thumpston J, Arya R. Risk factors for venous thrombosis in the black population. Thromb Haemost. 2003;90:835–838
  43. Oger E, Lacut K, Van Dreden P, Bressollette L, Abgrall JF, Blouch MT, et al. High plasma concentration of factor VIII coagulant is also a risk factor for venous thromboembolism in the elderly. Haematologica. 2003;88:465–469
  44. Tirado I, Mateo J, Soria JM, Oliver A, Martinez-Sanchez E, Vallve C, et al. The ABO blood group genotype and factor VIII levels as independent risk factors for venous thromboembolism. Thromb Haemost. 2005;93:468–474
  45. Bank I, Libourel EJ, Middeldorp S, Hamulyak K, van Pampus EC, Koopman MM, et al. Elevated levels of FVIII:C within families are associated with an increased risk for venous and arterial thrombosis. J Thromb Haemost. 2005;3:79–84
  46. Wells PS, Langlois NJ, Webster MA, Jaffey J, Anderson JA. Elevated factor VIII is a risk factor for idiopathic venous thromboembolism in Canada—Is it necessary to define a new upper reference range for factor VIII?. Thromb Haemost. 2005;93:842–846
  47. Kyrle PA, Minar E, Hirschl M, Bialonczyk C, Stain M, Schneider B, et al. High plasma levels of factor VIII and the risk of recurrent venous thromboembolism. N Engl J Med. 2000;343:457–462
  48. Legnani C, Mattarozzi S, Cini M, Cosmi B, Favaretto E, Palareti G. Abnormally short activated partial thromboplastin time values are associated with increased risk of recurrence of venous thromboembolism after oral anticoagulation withdrawal. Br J Haematol. 2006;134:227–232
  49. O’Donnell J, Mumford AD, Manning RA, Laffan M. Elevation of FVIII: C in venous thromboembolism is persistent and independent of the acute phase response. Thromb Haemost. 2000;83:10–13
  50. Kamphuisen PW, Houwing-Duistermaat JJ, van Houwelingen HC, Eikenboom HCJ, Bertina RM, Rosendaal FR. Familial clustering of factor VIII and von Willebrand factor levels. Thromb Haemost. 1998;79:323–327
  51. Kamphuisen PW, Lensen R, Houwing-Duistermaat JJ, Eikenboom HCJ, Harvey M, Bertina RM, et al. Heritability of elevated factor VIII antigen levels in factor V Leiden families with thrombophilia. Br J Haematol. 2000;109:519–522
  52. Schambeck CM, Hinney K, Haubitz I, Mansouri TB, Wahler D, Keller F. Familial clustering of high factor VIII levels in patients with venous thromboembolism. Arterioscler Thromb Vasc Biol. 2001;21:289–292
  53. Mansvelt EP, Laffan M, McVey JH, Tuddenham EG. Analysis of the F8 gene in individuals with high plasma factor VIII: C levels and associated venous thrombosis. Thromb Haemost. 1998;80:561–565
  54. Kamphuisen PW, Eikenboom HCJ, Rosendaal FR, Koster T, Blann AD, Vos HL, et al. High factor VIII antigen levels increase the risk of venous thrombosis but are not associated with polymorphisms in the von Willebrand factor and factor VIII gene. Br J Haematol. 2001;115:156–158
  55. De Visser MCH, Sandkuijl LA, Lensen RP, Vos HL, Rosendaal FR, Bertina RM. Linkage analysis of factor VIII and von Willebrand factor loci as quantitative trait loci. J Thromb Haemost. 2003;1:1771–1776
  56. Berger M, Mattheisen M, Kulle B, Schmidt H, Oldenburg J, Bickeboller H, et al. High factor VIII levels in venous thromboembolism show linkage to imprinted loci on chromosomes 5 and 11. Blood. 2005;105:638–644
  57. Scanavini D, Legnani C, Lunghi B, Mingozzi F, Palareti G, Bernardi F. The factor VIII D1241E polymorphism is associated with decreased factor VIII activity and not with activated protein C resistance levels. Thromb Haemost. 2005;93:453–456
  58. Nossent AY, Eikenboom HCJ, Vos HL, Bakker E, Tanis BC, Doggen CJM, et al. Haplotypes encoding the factor VIII 1241 Glu variation, factor VIII levels and the risk of venous thrombosis. Thromb Haemost. 2006;95:942–948
  59. Small M, Tweddel AC, Rankin AC, Lowe GD, Prentice CR, Forbes CD. Blood coagulation and platelet function following maximal exercise: Effects of beta-adrenoceptor blockade. Haemostasis. 1984;14:262–268
  60. O’Donnell J, Manning RA, Laffan MA. Beta-adrenergic receptor polymorphisms in patients with elevated factor VIII levels with venous thrombosis. Br J Haematol. 2003;123:139–141
  61. Nossent AY, Dai L, Rosendaal FR, Vos HL, Eikenboom HCJ. Beta 2 adrenergic receptor polymorphisms: Association with factor VIII and von Willebrand factor levels and the risk of venous thrombosis. J Thromb Haemost. 2005;3:405–407
  62. Saenko EL, Yakhyaev AV, Mikhailenko I, Strickland DK, Sarafanov AG. Role of the low density lipoprotein-related protein receptor in mediation of factor VIII catabolism. J Biol Chem. 1999;274:37685–37692
  63. Bovenschen N, Herz J, Grimbergen JM, Lenting PJ, Havekes LM, Mertens K, et al. Elevated plasma factor VIII in a mouse model of low-density lipoprotein receptor-related protein deficiency. Blood. 2003;101:3933–3939
  64. Cunningham N, Laffan MA, Manning RA, O’Donnell JS. Low-density lipoprotein receptor-related protein polymorphisms in patients with elevated factor VIII coagulant activity and venous thrombosis. Blood Coagul Fibrinolysis. 2005;16:465–468
  65. Henkens CM, Bom VJ, van der Meer J. Lowered APC-sensitivity ratio related to increased factor VIII-clotting activity. Thromb Haemost. 1995;74:1198–1199
  66. De Visser MCH, van Hylckama Vlieg A, Tans G, Rosing J, Dahm AE, Sandset PM, et al. Determinants of the APTT- and ETP-based APC sensitivity tests. J Thromb Haemost. 2005;3:1488–1494
  67. O’Donnell J, Mumford AD, Manning RA, Laffan MA. Marked elevation of thrombin generation in patients with elevated FVIII:C and venous thromboembolism. Br J Haematol. 2001;115:687–691
  68. van Hylckama Vlieg A, van der Linden IK, Bertina RM, Rosendaal FR. High levels of factor IX increase the risk of venous thrombosis. Blood. 2000;95:3678–3682
  69. Lowe G, Woodward M, Vessey M, Rumley A, Gough P, Daly E. Thrombotic variables and risk of idiopathic venous thromboembolism in women aged 45-64 years (Relationships to hormone replacement therapy). Thromb Haemost. 2000;83:530–535
  70. Weltermann A, Eichinger S, Bialonczyk C, Minar E, Hirschl M, Quehenberger P, et al. The risk of recurrent venous thromboembolism among patients with high factor IX levels. J Thromb Haemost. 2003;1:28–32
  71. Sweeney JD, Hoernig LA. Age-dependent effect on the level of factor IX. Am J Clin Pathol. 1993;99:687–688
  72. Khachidze M, Buil A, Viel KR, Porter S, Warren D, Machiah DK, et al. Genetic determinants of normal variation in coagulation factor (F) IX levels: genome-wide scan and examination of the FIX structural gene. J Thromb Haemost. 2006;4:1537–1545
  73. Gevers Leuven JA, Kluft C, Bertina RM, Hessel LW. Effects of two low-dose oral contraceptives on circulating components of the coagulation and fibrinolytic systems. J Lab Clin Med. 1987;109:631–636
  74. Naito K, Fujikawa K. Activation of human blood coagulation factor XI independent of factor XII (Factor XI is activated by thrombin and factor XIa in the presence of negatively charged surfaces). J Biol Chem. 1991;266:7353–7358
  75. Bouma BN, Griffin JH. Human blood coagulation factor XI (Purification, properties, and mechanism of activation by activated factor XII). J Biol Chem. 1977;252:6432–6437
  76. Minnema MC, Friederich PW, Levi M, von dem Borne PA, Mosnier LO, Meijers JC, et al. Enhancement of rabbit jugular vein thrombolysis by neutralization of factor XI (In vivo evidence for a role of factor XI as an anti-fibrinolytic factor). J Clin Invest. 1988;101:10–14
  77. Bouma BN, Meijers JC. Role of blood coagulation factor XI in downregulation of fibrinolysis. Curr Opin Hematol. 2000;7:266–272
  78. Meijers JC, Tekelenburg WL, Bouma BN, Bertina RM, Rosendaal FR. High levels of coagulation factor XI as a risk factor for venous thrombosis. N Engl J Med. 2000;342:696–701
  79. Eichinger S, Schönauer V, Weltermann A, Minar E, Bialonczyk C, Hirschl M, et al. Thrombin-activatable fibrinolysis inhibitor and the risk for recurrent venous thromboembolism. Blood. 2004;103:3773–3776
  80. Gerdes VE, Kraaijenhagen RA, Vogels EW, ten Cate H, Reitsma PH. Factor XI gene analysis in thrombophilia and factor XI deficiency. J Thromb Haemost. 2004;2:1015–1017
  81. Bouma BN, Meijers JC. Thrombin-activatable fibrinolysis inhibitor (TAFI, plasma procarboxypeptidase B, procarboxypeptidase R, procarboxypeptidase U). J Thromb Haemost. 2003;1:1566–1574
  82. Nesheim M. Thrombin and fibrinolysis. Chest. 2003;124(suppl):33S–39S
  83. van Tilburg NH, Rosendaal FR, Bertina RM. Thrombin activatable fibrinolysis inhibitor and the risk for deep vein thrombosis. Blood. 2000;95:2855–2859
  84. Juhan-Vague I, Renucci JF, Grimaux M, Morange PE, Gouvernet J, Gourmelin Y, et al. Thrombin-activatable fibrinolysis inhibitor antigen levels and cardiovascular risk factors. Arterioscler Thromb Vasc Biol. 2000;20:2156–2161
  85. Henry M, Aubert H, Morange PE, Nanni I, Alessi MC, Tiret L, et al. Identification of polymorphisms in the promoter and the 3’ region of the TAFI gene: Evidence that plasma TAFI antigen levels are strongly genetically controlled. Blood. 2001;97:2053–2058
  86. Tregouet DA, Aubert H, Henry M, Morange P, Visvikis S, Juhan-Vague I, et al. Combined segregation-linkage analysis of plasma thrombin activatable fibrinolysis inhibitor (TAFI) antigen levels with TAFI gene polymorphisms. Hum Genet. 2001;109:191–197
  87. Brouwers GJ, Vos HL, Leebeek FW, Bulk S, Schneider M, Boffa M, et al. A novel, possibly functional, single nucleotide polymorphism in the coding region of the thrombin-activatable fibrinolysis inhibitor (TAFI) gene is also associated with TAFI levels. Blood. 2001;98:1992–1993
  88. Frere C, Tregouet DA, Morange PE, Saut N, Kouassi D, Juhan-Vague I, et al. Fine mapping of quantitative trait nucleotides underlying thrombin-activatable fibrinolysis inhibitor antigen levels by a transethnic study. Blood. 2006;108:1562–1568
  89. Franco RF, Fagundes MG, Meijers JC, Reitsma PH, Lourenco D, Morelli V, et al. Identification of polymorphisms in the 5′-untranslated region of the TAFI gene: relationship with plasma TAFI levels and risk of venous thrombosis. Haematologica. 2001;86:510–517
  90. Morange PE, Aillaud MF, Nicaud V, Henry M, Juhan-Vague I. Ala147Thr and C+1542G polymorphisms in the TAFI gene are not asssociated with a higher risk of venous thrombosis in FV Leiden carriers. Thromb Haemost. 2001;86:1583–1584
  91. Zidane M, De Visser MCH, ten Wolde M, Vos HL, de Monye W, Bertina RM, et al. Frequency of the TAFI −438 G/A and factor XIIIA Val34Leu polymorphisms in patients with objectively proven pulmonary embolism. Thromb Haemost. 2003;90:439–445
  92. Zee RY, Hegener HH, Ridker PM. Carboxypeptidase B2 gene polymorphisms and the risk of venous thromboembolism. J Thromb Haemost. 2005;3:2819–2821
  93. Martini CH, Brandts A, de Bruijne EL, van HV, Leebeek FW, Lisman T, et al. The effect of genetic variants in the thrombin activatable fibrinolysis inhibitor (TAFI) gene on TAFI-antigen levels, clot lysis time and the risk of venous thrombosis. Br J Haematol. 2006;134:92–94
  94. Bertina RM, Koeleman BP, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature. 1994;369:64–67
  95. Kamphuisen PW, Rosendaal FR, Eikenboom HCJ, Bos R, Bertina RM. Factor V antigen levels and venous thrombosis: Risk profile, interaction with factor V Leiden, and relation with factor VIII antigen levels. Arterioscler Thromb Vasc Biol. 2000;20:1382–1386
  96. De Visser MCH, Poort SR, Vos HL, Rosendaal FR, Bertina RM. Factor X levels, polymorphisms in the promoter region of factor X, and the risk of venous thrombosis. Thromb Haemost. 2001;85:1011–1017
  97. von Kanel R, Wuillemin WA, Furlan M, Lammle B. Factor XII clotting activity and antigen levels in patients with thromboembolic disease. Blood Coagul Fibrinolysis. 1992;3:555–561
  98. Koster T, Rosendaal FR, Briët E, Vandenbroucke JP. John Hageman’s factor and deep-vein thrombosis: Leiden Thrombophilia Study. Br J Haematol. 1994;87:422–424
  99. Lavigne G, Mercier E, Quere I, Dauzat M, Gris JC. Thrombophilic families with inheritably associated high levels of coagulation factors VIII, IX and XI. J Thromb Haemost. 2003;1:2134–2139

PII: S0037-1963(07)00007-8

doi: 10.1053/j.seminhematol.2007.01.006

Seminars in Hematology
Volume 44, Issue 2 , Pages 77-84 , April 2007

Article Tools